This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Regulatory Shifts in Commission Credits Could Squeeze Cohen & Steers’ Research Budget and Profit Margins
Cohen & Steers, Inc. (CNS) has disclosed a new risk, in the Regulation category.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cohen & Steers, Inc. relies on commission credits generated from client securities transactions to fund a portion of its research and related services, helping to contain operating costs. If regulatory changes or evolving market practices restrict the generation or permitted use of these credits, the firm may be forced to absorb more research costs directly, pressuring operating margins and net income.
The average CNS stock price target is $63.00, implying -5.79% downside potential.
To learn more about Cohen & Steers, Inc.’s risk factors, click here.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
